Polylaminin Token
Blockchain Technology Supporting Spinal Cord Injury Research
100% of transaction fees donated to Polylaminin research at UFRJ
Our Mission
LAMINA is a cryptocurrency token dedicated to supporting groundbreaking research on Polylaminin, a revolutionary treatment for spinal cord injuries. Every transaction helps fund cutting-edge research that brings hope to millions.
Why LAMINA?
Blockchain Transparency
All donations are tracked on-chain, ensuring complete transparency and accountability
Groundbreaking Research
Supporting Dr. Tatiana Coelho's revolutionary Polylaminin research at UFRJ
100% Donation
All transaction fees go directly to the UFRJ Research Center
About Polylaminin
Polylaminin is an innovative polymeric form of the extracellular matrix protein laminin, derived from human placenta and transformed through chemical bonding into a high-molecular-weight biopolymer. It represents over 25 years of dedicated research conducted by scientists at the Federal University of Rio de Janeiro (UFRJ) in strategic collaboration with Cristália laboratory, a leading national biotechnology pharmaceutical company.
Pre-clinical studies conducted at UFRJ have revealed extraordinary results: a single intrathecal application of Polylaminin demonstrated the ability to induce robust axonal regeneration and complete restoration of locomotor function in animal models with complete spinal cord injury. The findings indicate revolutionary potential for treating spinal cord injuries in humans.
Meet Dr. Tatiana Coelho
Dr. Tatiana Coelho de Sampaio
Dr. Tatiana Coelho has been leading research on laminin since the 1990s. Her groundbreaking work on Polylaminin has brought hope to patients with spinal cord injuries worldwide. In January 2026, ANVISA authorized clinical trials to evaluate the safety of Polylaminin in humans, marking a historic milestone in Brazilian medical research.
Key Achievements:
Professor at UFRJ since 1995
PhD in Sciences from UFRJ
Post-doctoral fellow at University of Illinois, USA
Post-doctoral fellow at University of Erlangen-Nuremberg, Germany
Over 25 years of research on laminin and neural regeneration
Clinical Progress
In January 2026, ANVISA authorized the first clinical trial to evaluate the safety of Polylaminin in humans. This Phase 1 study represents a crucial step toward making this treatment available to patients.
Polylaminin is one of the strategic themes of ANVISA's Innovation Committee, created in 2025 to monitor and evaluate innovative products and technologies considered priorities for public health in Brazil.
Scientific Publications
Peer-Reviewed Research
Groundbreaking study published in the FASEB Journal demonstrating Polylaminin's efficacy in promoting axonal regeneration and functional recovery in spinal cord injury models.
Comprehensive research documentation on ResearchGate detailing the development and application of Polylaminin in treating spinal cord injuries.
Research Impact
These groundbreaking peer-reviewed publications, pioneered by Dr. Tatiana Coelho and her research team at UFRJ, have definitively established Polylaminin as one of the most promising therapeutic breakthroughs for spinal cord injury treatment in modern neuroscience. Published in prestigious international journals, this research has garnered extensive citations from the global scientific community and serves as the cornerstone for the current Phase 1 clinical trials authorized by ANVISA, bringing renewed hope to millions of patients worldwide.
Real Patient Cases
Documented results from experimental applications and clinical studies with Polylaminin
Experimental Phase Results
Group of 8 volunteers treated between 2018 and 2021 in the acute phase, up to 72 hours after trauma, with application during surgery.
2018-2021Complete Recovery Cases
Some patients showed complete recovery of movement with no aftereffects, resuming routine without restrictions after treatment.
2021Treatment Window
Polylaminin is most effective when administered within 72 hours of spinal cord injury, during the acute phase.
2025Important Clinical Information
All documented cases are part of experimental research or compassionate use authorized by court orders. Polylaminin is still in Phase 1 clinical trials.
Phase 1 Study - 2026
ANVISA authorized Phase 1 clinical trial with 5 volunteers to evaluate the safety of Polylaminin in humans.
Tokenomics
Contract Address
0x00000000000000000000000000000000000000001,000,000,000
LAMINA
100% of fees
Transparent On-ChainUFRJ Research Center
Federal University of Rio de Janeiro
Ready to Support the Research?
Every LAMINA token you acquire contributes directly to groundbreaking spinal cord injury research. Join us in making a difference.
Research & News
Forbes profiles the pioneering researcher whose Polylaminin breakthrough is bringing hope to spinal cord injury patients worldwide
Ministry of Health and ANVISA announce approval of clinical study for innovative spinal cord injury treatment
Learn about the UFRJ researcher who has dedicated over 25 years to developing this breakthrough treatment
Understanding the exceptional judicial access to this promising biopharmaceutical
Clinical trials registry reports laboratory statement that deaths were unrelated to the drug, citing severe pre-existing conditions
Polylaminin, considered capable of reversing spinal cord injury, is presented by Cristália laboratory after 25 years of research
Professor Tatiana Sampaio from UFRJ leads research focused on neural regeneration in spinal cord injury cases